Fifteen-year mortality after radical prostatectomy: Which factors are available for patient counselling?

Scandinavian Journal of Urology

Volumn 48, Issue 2, 2014, Pages 123-130

  Wæhre, Håkon ^a   Vlatkovic, Ljiljana ^a   Cvancarova, Milada ^a   Paus, Elisabeth ^a   Fosså, Sophie D ^a   Danielsen, Håvard E ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

15 year prostate specific survival; Biochemical relapse; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; COUNSELING; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

ADULT; AGED; DIRECTIVE COUNSELING; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 84896118050     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.3109/21681805.2013.817483     Document Type: Article

References (30)

1. Kibel AS, Ciezki JP, Klein EA, Reddy CA, Lubahn JD, Haslag-Minoff J, et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol 2012;187:1259-65.
2. Abdollah F, Sun M, Schmitges J, Thuret R, Bianchi M, Shariat SF, et al. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. J Urol 2012;188:73-83.
3. Dorin RP, Daneshmand S, Lassoff MA, Cai J, Skinner DG, Lieskovsky G. Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era. Urology 2012;79:626-31.
4. Isbarn H, Wanner M, Salomon G, Steuber T, Schlomm T, Köllermann J, et al. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int 2009;106: 37-43.
5. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003;21:2163-72. (Pubitemid 46606365)
6. Boorjian SA, Karnes J, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 2011;117:2883-91.
7. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364:1708-17.
8. Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27: 4300-5.
9. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011;185: 869-75.
10. Kvåle R, Auvinen A, Adami HO, Klint A, Hernes E, Møller B, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007;99:1881-7. (Pubitemid 351767195)
11. Paus E, Nilsson O, Børmer OP, Fosså SD, Otnes B, Skovlund E. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia. J Urol 1998;159:1599-605. (Pubitemid 29117349)
12. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509.
13. Berg A, Lilleby W, Bruland øS, Fosså SD. 10-year survival and quality of life in patients with high-risk pN0 prostate cancer following definitive radiotherapy. Int J Rad Oncol Biol Phys 2007;69:1074-83. (Pubitemid 47625832)
14. Bolla M, Van Tienhoven G, Warde P, Dubois BD, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. Lancet Oncol 2010;11:1066-73.
15. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG- 7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301-8.
16. Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011;378:2104-11.
17. Busch J, Stephan C, Herold A, Erber B, Kempkensteffen C, Hinz S, et al. Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a singlecentre experience. BJU Int 2012;110:E985-90.
18. Boorjian SA, Karnes J, Rangel LJ, Bergstralh EJ, Blute ML. Mayo Clinic Validation of the D'Amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008;179:1354-61.
19. Boorijan SA, Tollefson MK, Thompson RH, Rangel LJ, Bergstralh EJ, Karnes RJ. Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy. J Urol 2012;188:1761-6.
20. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367: 203-13.
21. Vickers A, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A, et al. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group Randomized Trial. Eur Urol 2012;62:204-9.
22. Abdollah F, Sun M, Schmitges J, Thuret R, Bianchi M, Shariat SF, et al. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patients characteristics. J Urol 2012;188:73-83.
23. Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, et al. A critical analysis of long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 2012;61:664-75.
24. Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, et al. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int 2012;110: 1122-8.
25. Froehner M, Koch R, Litz RJ, Hakenberg OW, Wirth MP. Which patients are at the highest risk of dying from competing causes £ 10 years after radical prostatectomy? BJU Int 2012;110:206-10.
26. Korets R, Seager CM, Pitman MS, Hruby GW, Benson MC, McKiernan JM. Effects of delaying surgery on radical prostatectomy outcomes: a contemporary analysis. BJU Int 2011; 110:211-16.
27. Holmstrøm B, Holmberg E, Egevad L, Adolfsson J, Johansson JE, Hugosson J, et al. Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden follow-up study. J Urol 2010;184: 1322-7.
28. Sun M, Abdollah F, Hansen J, Trinh QD, Bianchi M, Tian Z, et al. Is a treatment delay in radical prostatectomy safe in individuals with low-risk prostate cancer? J Sex Med 2012;9:2961-9.
29. Fall K, Strömberg F, Rosell J, Andrén O, Varenhorst E; South-East Region Prostate Cancer Group. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol 2008;42:352-7.
30. Hole KH, Axcrona K, Lie AK, Vlatkovic L, Geier OM, Brennhovd B, et al. Routine pelvic MRI using phased-array coil for detection of extraprostatic tumour extension: accuracy and clinical significance. Eur Radiol 2013;23: 1158-66.